drugset
drugset / Trial / NCT06739928

Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC

NCT06739928 ↗

Phase 2 Recruiting 120 enrolled Guangzhou Institute of Respiratory Disease
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a prospective, randomized, parallel, multicenter phase II study aimed at evaluating the efficacy and safety of irinotecan liposome (II) or etoposide combined with adebrelimab and carboplatin as first-line treatment for extensive stage small cell lung cancer. The primary endpoint of the study was the 1-year overall survival rate.

Timeline

Start
2025-01-01
Primary completion
2026-06-30
Completion
2027-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Etoposide Small molecule — —
Subject irinotecan liposome (II) Unknown — —
Background Adebrelimab Monoclonal antibody — —
Background Carboplatin Small molecule — —

Indications

small cell lung carcinoma